FIGURE LEGENDS
FIGURE 1 . Hematoxylin-eosin staining of biopsied tumor tissue (×400).
FIGURE 2. Magnetic resonance imaging (MRI) and18fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) showing the primary tumor before the initiation of chemoradiotherapy. (A) MRI axial plane. (B) MRI sagittal plane. (C) FDG-PET axial plane.
FIGURE 3. Computed tomography (CT) and18fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) showing multiple lymphadenopathy before the initiation of chemoradiotherapy. (A–C) CT image showing enlarged lymph nodes in the external iliac-, common iliac-, and para-aortic-lymph node regions, respectively. (D–F) FDG-PET images corresponding to A–C.
FIGURE 4. Schematic presentation of the treatment protocol. CS, central shielding; CRP, serum C-reactive protein; fr, fractions; G-CSF, serum granulocyte-colony stimulating factor; ICBT, intracavitary brachytherapy; LN, lymph node; PALN, para-aortic lymph node; Prophyl, prophylactic; RT, radiotherapy; WBC, white blood cell count in the peripheral blood; WP, whole pelvis.
FIGURE 5. Magnetic resonance imaging (MRI) and computed tomography (CT) after completion of chemoradiotherapy. (A, B)MRI of axial and sagittal planes, respectively, showing the uterine cervix. (C–E) CT image showing the external iliac-, common iliac-, and para-aortic-lymph node regions, respectively.
FIGURE 6. Computed tomography (CT) at 2 months after completion of chemoradiotherapy. Metastatic tumors (arrows) in (A) the left supraclavicular lymph node, (B) the liver, and (C, D) the lung.
FIGURE 7. Kinetics of laboratory markers during the clinical course. CRP, serum C-reactive protein; G-CSF, serum granulocyte-colony stimulating factor; SCC, serum squamous cell carcinoma antigen; and WBC, white blood cell count in the peripheral blood.